07-05-2021 11:30 via medpagetoday.com

FDA Advisors Split on New Drug for Vasculitis

(MedPage Today) -- Members of an FDA advisory panel were sharply divided as to whether avacopan, an oral small molecule inhibitor of the C5a receptor, was sufficiently safe and effective for treating antineutrophil cytoplasmic antibody (ANCA)-associated...
Read more »